UK biotech Astex has hailed the US approval and launch of Novartis’ latest breast cancer drug, ribociclib – which the Cambridge-based firm helped to discover and develop. Formed in 1999 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback